{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T09:06:42Z","timestamp":1754557602554},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The objective of this study was to report the tolerability and toxicity of a regimen consisting of intravenous (IV) docetaxel and intraperitoneal (IP) cisplatin and paclitaxel with granulocyte colony-stimulating factor support.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>We conducted a retrospective cohort study of patients with surgical stage II-IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma treated with an outpatient IP chemotherapy regimen consisting of docetaxel 75\u2009mg\/m<jats:sup>2<\/jats:sup> IV and cisplatin 75\u2009mg\/m<jats:sup>2<\/jats:sup> IP day 1 followed by paclitaxel 60\u2009mg\/m<jats:sup>2<\/jats:sup> IP day 8 every 21 days. Grade 3 and 4 toxicity, dose delays and reductions, port complications, and tolerability are reported. Outcomes, including response rate, progression-free survival (PFS), overall survival (OS) are also reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 60 patients received this IP regimen. Most common toxicities included neutropenia (47%), gastrointestinal (28%), and anemia (25%). Most patients (85%) experienced no IP port complications. Dose delay or reduction was required in 30% of patients. Two-thirds completed all prescribed cycles, with 80% of total planned cycles completed. Complete response was achieved for 88%, and 43% are currently without evidence of disease. Median PFS for all patients was 25.5 months (95% confidence interval [CI], 20.4-30.5\u2009mo) while OS for all patients was 56.8 months (95% CI, 47.7-65.9\u2009mo). For the 44 patients with stage III disease, median PFS was 22.1 months (95% CI, 16.3-28.0\u2009mo), while median OS was 56.8 months (95% CI, 47.3-66.3\u2009mo).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This docetaxel-based IP chemotherapy regimen demonstrates an improved tolerability profile compared with GOG172. Additional evaluations on alternative IP regimens remain warranted. Short follow-up time limits survival assessment, but results are encouraging.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000468","type":"journal-article","created":{"date-parts":[[2018,5,20]],"date-time":"2018-05-20T01:19:31Z","timestamp":1526779171000},"page":"12-16","source":"Crossref","is-referenced-by-count":4,"title":["Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma"],"prefix":"10.1097","volume":"42","author":[{"given":"David A.","family":"Becker","sequence":"first","affiliation":[{"name":"Department of Obstetrics & Gynecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christen L.","family":"Walters-Haygood","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brentley Q.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri S.","family":"Bevis","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"R9-20230903","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1525-1438.2007.01100.x","article-title":"National Cancer Institute-United States strategy regarding intraperitoneal chemotherapy for ovarian cancer","volume":"18","author":"Trimble","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000356758","article-title":"Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer","volume":"59","author":"Battelli","year":"2013","journal-title":"Chemotherapy"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/AOG.0000000000001436","article-title":"Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer","volume":"127","author":"Wright","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"suppl","key":"R13-20230903","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1200\/JCO.2016.34.15_suppl.5504","article-title":"Multicenter phase II study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma (abstr 5504)","volume":"34","author":"Hasegawa","year":"2016","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"R14-20230903","article-title":"OV21\/PETROC: a randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC) (abstr LBA5503)","volume":"34","author":"Mackay","year":"2016","journal-title":"J Clin Oncol"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ygyno.2008.12.035","article-title":"An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer","volume":"113","author":"Berry","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels","volume":"19","author":"Rustin","year":"2001","journal-title":"J Clin Oncol"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1054\/bjoc.2000.1572","article-title":"Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer","volume":"84","author":"Vasey","year":"2001","journal-title":"Br J Cancer"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ygyno.2008.10.025","article-title":"The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies","volume":"112","author":"Whitworth","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-9966-31-14","article-title":"Therapeutic strategies in epithelial ovarian cancer","volume":"31","author":"Kim","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol oncol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1471-0528.2011.03179.x","article-title":"Ports and complications for intraperitoneal chemotherapy delivery","volume":"119","author":"Helm","year":"2012","journal-title":"BJOG"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201901000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:07:16Z","timestamp":1693710436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201901000-00003"}},"subtitle":["A Continued Need for Ovarian Cancer Patients"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000468","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}